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Acute kidney injury (AKI) remains a major clinical event with rising incidence, severity, and cost; it now has a 
morbidity and mortality exceeding acute myocardial infarction. There is also a documented conversion to and 
acceleration of chronic kidney disease to end-stage renal disease. The multifactorial nature of AKI etiologies and 
pathophysiology and the lack of diagnostic techniques have hindered translation of preclinical success. An evolving 
understanding of epithelial, endothelial, and inflammatory cell interactions and individualization of care will result 
in the eventual development of effective therapeutic strategies. This review focuses on epithelial and endothelial 
injury mediators, interactions, and targets for therapy.
Introduction
Acute kidney injury (AKI) has become the focus of intense epi-
demiologic, clinical, translational, and basic science research. This 
focus is well deserved given an incidence of 21.6% for all hospital-
ized adults worldwide (1), mortality of 23.9%, and morbidity with 
known association for accelerating chronic kidney disease (CKD) 
to end-stage renal disease (ESRD) (2–4). Due to this increased 
interest, the literature abounds with exciting data, from the newly 
documented involvement of innate and adaptive immunity to 
novel biomarkers and numerous ongoing or planned phase I and 
II clinical trials. Indeed, the data are robust, multidimensional, 
and have provided great insight into the complex pathophysiology 
and numerous cellular processes involved. Cell-cell interactions 
involving all cell types within the kidney and the entire host of 
immune cells have been documented (5). Epidemiologic studies 
have allowed classification of patient populations at higher risk 
for developing AKI with diseases or who are undergoing proce-
dures that reduce renal blood flow. Extensive and well-planned 
biomarker studies, primarily in postoperative cardiovascular 
patients, have provided multiple opportunities for future explo-
ration, and urinary and serum biomarker identification continues 
to outpace the ability to test their clinical utility (6, 7). AKI trial 
networks have been established, and interactions between neph-
rologists, critical care specialists, anesthesiologists, and cardiol-
ogists have led to networks and interactions, such as the Acute 
Dialysis Quality Initiative (ADQI), Acute Kidney Injury Network 
(AKIN), and Translational Research Investigating Biomarker End-
points-AKI (TRIBE-AKI), which have been especially beneficial 
to progress in the field. An NIH-funded George M. O’Brien P-30 
between the University of Alabama at Birmingham and the Univer-
sity of California, San Diego is currently providing a platform to 
translate basic research to clinical studies in AKI.
Despite numerous positive studies, the translation of this new 
information into clinical therapies has been slow. The goal of this 
review is to delineate recent advances in our understanding of the 
basic biology of AKI and to place this into a clinical context with 
an eye toward successful therapeutic translation. The reader is also 
referred to recent in-depth reviews on AKI pathophysiology that 
falls outside the scope of this work (5, 8).
The heterogeneous nature of AKI
AKI has numerous etiologies that all result in nearly the same 
structural and functional readout. AKI-initiating events are 
often multifactorial and occur in a heterogeneous patient pop-
ulation with differences in genetics, age, kidney functional sta-
tus, and accompanying comorbidities. Furthermore, the multi-
ple pathophysiologic processes, including necrosis, apoptosis, 
mesenchymal transformation, cellular infiltration, coagulation, 
and complement activation that contribute to AKI and the mul-
titude of cell types and processes within the innate and adaptive 
immune response contribute to a nearly infinite combination of 
events and processes to consider (Figure 1). Furthermore, these 
processes may be histologically focal in nature (9), and we lack 
adequate clinical diagnostic and quantification techniques to 
allow for early detection, injury quantification, and therapeutic 
evaluation. There are limited data to describe the human disease; 
when it is forthcoming, it is without a predominant pattern on 
which to base therapy (9). In preclinical studies we all too often 
use nonspecific, regional (i.e., cortical versus medullary) rather 
than cell-specific data to characterize pathophysiological events. 
This results in confusion as to which cell type is responsible for 
the detected signal (wbcs versus epithelial versus endothelial). 
Finally, we design and test our therapies in otherwise physiolog-
ically normal inbred rat or mouse strains when we know AKI is 
more likely to occur in patients with underlying comorbidities, 
especially CKD, reduced cardiac output, or aging. We frequently 
use only one AKI model to delineate efficacy when we know there 
are marked immune response differences between rats and mice 
(10), and we do not know which is more representative of humans. 
Importantly, we do know that genomic responses in mouse mod-
els of sepsis do not mimic human inflammatory disorders (11).
Cell types and processes involved in AKI
The AKI field has expanded rapidly as the injury-stimulated 
responses of the innate and adaptive immune systems have been 
delineated (12–17). Under physiologic conditions the heteroge-
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neous cell populations within and circulating through the kidney 
function together to perform a number of complex processes in 
a coordinated fashion. Ischemia, sepsis, and nephrotoxins dis-
rupt these processes and lead to a coordinated response that has 
evolved for survival of the animal; thus, we should not always 
equate these events with maladaptation and try to eliminate all 
or most in our pursuit for therapeutic success. In animals and 
humans with normal underlying physiology and mild to mod-
erate AKI, these processes bring about cellular repair and tissue 
healing, with a high percentage of individuals returning to normal 
or near-normal kidney function. As shown in Figure 1, the activa-
tion and resolution of this process is dependent upon the extent of 
injury. Therefore, with more severe or repeated injuries, especially 
in at-risk models or humans with underlying comorbidities, the 
prognosis is far worse (5, 18–20). It is essential that we understand 
what occurs in the at-risk kidney and use at-risk models in preclin-
ical studies to test hypotheses and therapeutic agents if we are to 
prevent or minimize AKI-induced progression of CKD to ESRD.
Immune response and involvement in AKI
Recent attention has turned to understanding the role of the 
immune response to AKI from both sepsis and ischemia. Virtu-
ally all wbc types have been implicated in this response, and either 
deletion or enhancement of each cell’s response has been shown 
to result in an improved short-term outcome (16). In particular, 
the role of polymorphonuclear cells (PMNs) (21–23), monocytes/
macrophages (24–27), NKT (28, 29), NK (30), Tregs (31–33), and 
B cells (14, 34) have been investigated. The time course of circu-
lating cell involvement varies by the cell type (28, 35) with PMNs 
leading the way, followed by monocytes/macrophages, in both the 
rapidity of response and numbers of cells. Most invading cells are 
detrimental, but some, such as Tregs, are beneficial (31–33), and 
enhancing Tregs using IL-2 complexes reduced histologic injury 
and improved function in mice (36). Macrophages play a special 
role because type 1 macrophages arrive early and mediate cellular 
injury, but type 2 macrophages are essential for normal repair later 
in the process (25, 26, 37). Persistence of type 1 macrophages has 
been associated with lack of healing and CKD progression in mice 
(38). Numerous reviews cover the involvement of infiltrating cells 
in AKI, and therapeutic attempts are being undertaken to modu-
late this invasion and limit its associated damage (39).
The initial alarm sounded immediately after epithelial and 
endothelial cell injury triggers an immune response, which is then 
amplified by the recruitment and subsequent invasion of wbcs. 
Activation of the epithelial/endothelial axis, as the proximal event 
in injury, will serve as the focus of the remainder of the review 
and is of particular interest for two therapeutic reasons. First, the 
inflammatory cell invasion would not occur without alarm signals 
being generated and sent out from endogenous kidney cells; thus, 
minimizing the subsequent distal cascades depends on targeting 
early events in these cells. Second, the possibility of providing the 
necessary time-dependent selective immune modulation required 
to control the immune reaction locally within the kidney comes 
with substantial clinical infection risks to patients when using 
present day, nonselective, immune-suppressing therapies.
Tubular epithelial cells, DCs, pericytes, and ECs (Figure 2) make 
up the epithelial/endothelial axis and serve as the resident cellu-
lar unit responsible for sensing and mediating the initial signals 
Figure 1
The complex and overlapping nature of AKI. (A) 
Human kidney biopsy with normal cortical morphol-
ogy. Note the cuboidal PTCs and closely packed 
tubules surrounded by microvasculature. (B) Human 
kidney biopsy with ischemic injury (outer stripe). 
Note the markedly injured PTCs with loss of the api-
cal microvilli and the large number of wbcs occluding 
flow within the peritubular capillaries, the rouleaux 
formation, and the marked expansion of the inter-
stitial space. This area of the kidney is especially 
prone to ongoing vascular congestion after injury, 
resulting in lack of reperfusion and continuing cel-
lular injury. (C) Multiple cellular injury processes in 
resident kidney cells lead to local injury and systemic 
signals for recruitment of circulating wbcs, including 
PMNs, monocytes, NKTs, Tregs, NK cells, CD4+, 
CD8+ T cells, and B cells. These cells magnify the 
ongoing inflammatory process with enhanced resi-
dent cell activation (DCs, pericytes, macrophages), 
cellular dedifferentiation, myofibroblast formation, 
and ultimately fibrosis and microvascular dropout. 
The extent of injury determines the level of process 
activation (inset).
Downloaded from http://www.jci.org on December 23, 2016.   https://doi.org/10.1172/JCI72269
review series
 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 6   June 2014 2357
in response to toxic, ischemic, and sepsis-induced injury. Both 
proximal tubule cells (PTCs) and thick ascending limb (TAL) cells 
have been shown to be involved as sensors, effectors, and injury 
recipients of AKI stimuli. Early events and subsequent signaling 
from these cells initiate complex and multidimensional cascades 
that mediate AKI pathophysiology. Controlling these early events 
offers the best approach to a successful therapy due to limiting the 
number of downstream targets.
Proximal tubule cells 
The PTC response to ischemia is characterized by actin cytoskeletal 
aggregation and derangement resulting in apical membrane bleb-
bing, tight junction opening, loss of surface membrane polarity, 
and cell detachment from focal adhesions (refs. 40–43, Figure 3, A 
and B, and Supplemental Videos 1 and 2; supplemental material 
available online with this article; doi:10.1172/JCI72269DS1); 
these alterations are commensurate with the degree of injury. 
Figure 2
Alterations in the epithelial/endothelial axis during AKI. (A) Human kidney biopsy with ischemic AKI (cortical area). Note the expanded interstitium, 
microvascular plugging, dilated tubules, and patchy nature of injury. (B) Under physiologic conditions, coordinated communication and cell-cell 
interactions maintains homeostasis with normal kidney function. Epithelial injury leads to apoptotic and necrotic cell death that is accompanied 
by cytokine, chemokine, and ROS release. These factors initiate the release of exogenous and endogenous DAMPS by resident cells, leading to 
activation and further injury. These signals also initiate the infiltration of professional inflammatory cells such as PMNs and monocytes, leading 
to enhanced inflammation and further cell injury and destruction. Inflammatory signals produce alterations in the endothelium, resulting in loss 
of cell-cell contact and breakdown of the ECM. Additionally, there is marked microvascular plugging mediated by adherent wbcs and rouleaux 
formation, leading to reduced flow and worsening ischemia. Subsequently, there is migration of some of these cells into the interstitium. Pericytes 
dissociate from underlying ECs and convert into myofibroblasts, which lay down collagen to initiate the fibrotic cycle.
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Mitochondrial alterations include fragmentation with reduction 
in ATP-generating capacity, enhanced production of ROS, and 
mitochondrial permeability transition pore opening; minimiz-
ing these mitochondrial events selectively reduces injury (44, 45). 
Mitochondrial dynamics have emerged as an important aspect in 
AKI cellular injury (46). Mitochondrial fission occurs during stress 
or cell ischemic injury, leading to enhanced BAX/BAK sensitivity 
and apoptosis (47–49). Additionally, there is marked upregulation 
(50, 51) of apoptotic regulators (p53) (5, 52), initiators (caspases) 
(53–55), and protective genes (heme oxygenase, refs. 56–58; and 
heat shock proteins, ref. 59). Increases in p53 expression, an early 
initiator of the apoptotic cascade, lead to the upregulation of the 
distal apoptotic mediators BAX, PUMA-α, p21, and Siva (52, 60). 
PTC-selective inhibitors of p53 upregulation, using either siRNA 
or PTC-specific knockouts, leads to protection from ischemia (52, 
60). Thus, PTC-mediated injury initiates a cascade of signals start-
ing the injury cycle. The extent of this cascade is proportional to 
the level of injury (Figure 1).
PTCs have been shown to serve as a sensor of both self and 
non-self danger-associated molecular patterns (DAMPS) and 
pathogen-associated molecular patterns (PAMPS) using pattern 
recognition receptors (PRRs) such as TLR4 (12, 61). PTC TLR4 is 
upregulated and migrates to the apical domain in response to LPS 
in S1 PTCs, the earliest epithelial cells downstream of glomeru-
lar filtration (62). Interestingly, the S1 cell internalizes and pro-
cesses LPS via TLR4, but is protected from injury by upregulated 
defense mechanisms, including expression of the cytoprotective 
proteins HO-1 and SIRT1. However, S2/3 cells undergo oxidative 
injury with minimal uptake of LPS, implying communication 
between the segments following LPS exposure (63). This injury 
is dependent on CD14 and is likely due to peroxisomal disrup-
tion, perhaps mediated by TNF-α, as it is independent of systemic 
cytokines. TLRs also play a critical role in ischemic injury, because 
loss of epithelial TLR4 and MyD88 (35) or TLR2 (50) results in 
reduced cytokine and chemokine production and minimization 
of wbc infiltration and kidney dysfunction. Thus, TLR-mediated 
LPS signaling in PTCs serves as an early initiator of damage- 
associated signaling cascades.
PTCs release cytokines and chemokines in response to cell 
injury, and these agents have direct effects on endothelial func-
tion. A series of elegant studies directly demonstrated this phe-
nomenon using fluorescent cytopathologic E. coli that were 
microinjected into early PT segments, with cellular and physio-
logic responses recorded using two-photon microscopy (64–66). 
Attachment to the apical membrane, but without penetration 
into or through the PTC monolayer barrier, resulted in rapid and 
selective termination of blood flow to the adjacent area, leading to 
vascular isolation of the infected area with localized hypoxia, wbc 
migration/infiltration, and necrosis. The same E. coli strain, miss-
ing only one virulence factor, required a far greater time to initiate 
this protective process. Tissue concentrations of cytokines were 
markedly elevated in the affected area, but were undetectable adja-
cent to the injected areas (66). Finally, prevention of this microvas-
cular response resulted in widespread organ dissemination of the 
injected E. coli and death of the rat within 24 hours, which was not 
observed with the intact system (66). These experiments demon-
strate that PT-mediated detection of infectious agents and subse-
quent signal communication between PTCs and ECs leads to local-
ization of the infecting agent and prevention of systemic spread.
Another area of progress has been an increase in our under-
standing of PTC repair following severe injury. Increasing the 
duration of ischemia results in worse cell injury, reduced func-
tion, and longer recovery periods (42, 43). Pioneering work in rats 
using the renal artery clamp model revealed that PTCs recovered 
rapidly and completely following mild ischemia via cellular repair. 
As ischemia duration increases, loss of PTCs into the lumen as 
well as necrosis and apoptosis increases, indicating that recovery 
of tubular cell integrity and function likely requires new cells. 
Studies using chimera and genetic fate-tracing strategies largely 
discredited the idea that migration of extratubular stem or pro-
genitor populations into the tubule was a source of these new 
cells (67, 68). A follow-up study examined lineage, and clonal 
behavior of fully differentiated PTCs after injury and found that 
Figure 3
Ischemic injury–induced alterations in the proximal tubules (PTs) and 
microvasculature. (A) A portion of the superficial PTs was transfected 
with GFP-actin using an adenovirus vector. Following i.v. infusion of 
a small, filterable red dextran, ischemia was induced for 25 minutes, 
and then blood flow was returned just prior to imaging the area. A sin-
gle plane from a 3D volume video shows GFP-actin–containing blebs 
being released from the microvillar membrane (arrows). (B) Lumen of 
a tubule in cross-section filled with freely filtered red dextran–contain-
ing blebs (arrows) flowing down the nephron and forming a cast. The 
video for B was stitched together from two successively acquired time 
series. Scale bar: 20 μm. (C) Rhodamine-conjugated dextran (red) is 
seen circulating within the peritubular microvasculature under physi-
ologic conditions. Flow rates for rbcs, appearing as dark streaks sur-
rounded by bright-red plasma, are high. With the addition of a nuclear 
dye (white), a fast-flowing wbc can be seen streaking through the 
vasculature (arrow). Note the absence of red dextran in the interstitial 
space (asterisks). (D) Rat kidney 24 hours after ischemic injury. Here, 
activated wbcs with distinguishable Hoechst-labeled nuclei (arrows, 
nuclei in blue) crawl and roll along the vasculature, slowing down rbc 
flow. Vessel wall integrity shows heterogeneous areas of damage as 
the large 150-kDa dextran leaks into the interstitial space (asterisks). 
The rbc flow rates are markedly reduced due to wbc and rouleaux-
mediated obstruction. Scale bar: 20 μm.
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both cellular repair and proliferation occurred and clonal growth 
was greater with increased severity of injury (69). These data pro-
vide further evidence that terminally differentiated epithelia are 
able to proliferate and indicate that therapy that minimizes PTC 
injury will reduce cellular death and detachment, allowing for a 
greater percentage of cells to recover by undergoing cellular repair 
and reducing the injury signaling cascade.
Uromodulin (UMOD) is a heavily glycosylated protein that is 
uniquely produced in the kidney by TAL cells (70, 71). Interest-
ingly, UMOD appears to be an essential effector produced dur-
ing kidney injury to modulate innate immunity and inflamma-
tion (12, 70, 72, 73). Umod knockout mice subjected to ischemia/
reperfusion injury (IRI) showed increased S3 injury and necrosis 
compared to WT controls (72, 74). This injury was associated 
with increased neutrophil infiltration in the outer medulla and 
increased expression of TLR4 and CXCL2 by S3 segments (72, 74). 
Neutralization of CXCL2 was protective, suggesting that a TLR4/
CXCL2 proinflammatory pathway may be important in patho-
physiology and supports UMOD-dependent TAL/S3 crosstalk. 
Indeed, after IRI, UMOD trafficking shifted towards the intersti-
tium and basolateral aspects of S3 segments (73), where a puta-
tive receptor for UMOD is expressed (72). This translocation of 
UMOD was not the result of TAL-altered polarity. Furthermore, 
a significant increase in UMOD levels was shown in the kidney 
at the onset of recovery, concomitant with the suppression of 
tubular-derived cytokines and chemokines such as MCP-1. These 
results indicate that UMOD-mediated protective crosstalk may be 
important in enhancing recovery from AKI (73), again supporting 
the early and essential role of signaling by epithelial cells.
PTCs and TAL cells sense their environment and rapidly initi-
ate a signaling cascade in response to ischemia, toxins, DAMPS, 
and cellular injury. This early sequence of events is the founda-
tion for subsequent events, and the response is proportional to 
the severity of the inciting event(s). Therapeutic interventions to 
minimize the resulting signaling cascades appear to be a primary 
way to reduce acute injury, downstream inflammation, and sub-
sequent chronic injury.
Endothelium
The microvasculature and ECs in particular regulate blood flow 
to local tissue beds and modulate coagulation, inflammation, and 
vascular permeability. AKI has profound effects on the renal endo-
thelium resulting in microvascular dysfunction leading to ongo-
ing ischemic conditions and further injury following the initial 
insult (75, 76). Reduced rbc flow, vascular congestion, edema, and 
rolling and adherence of inflammatory cells on the endothelium 
leads to the extension phase of AKI (refs. 2, 75, 77, 78, Figure 3, C 
and D, and Supplemental Videos 3 and 4). Total renal blood flow 
(RBF) may have little bearing on regional microvascular flow and 
as human biopsies show, patchy areas of injury (9, 79). Therefore, 
understanding microvascular flow is far more important than 
total RBF and represents an attractive therapeutic target.
Endothelial cells play a central role in coagulation via interaction 
with protein C (PC) through the EC protein C receptor (EPCR) 
and thrombomodulin (80). PC is activated by thrombin-mediated 
cleavage, and the rate of this reaction is amplified three orders 
of magnitude by thrombin/thrombomodulin binding (81). The 
activation rate of PC is further increased approximately 10-fold 
when EPCR binds PC and presents it to the thrombin/thrombo-
modulin complex (81). Activated PC (aPC) has antithrombotic/
profibrinolytic properties, participates in numerous antiinflam-
matory and cytoprotective pathways to restore homeostasis, and 
has been shown to ameliorate LPS-induced AKI via downregula-
tion of iNOS and angiotensin-2 (82–84). During an inflamma-
tory response, many natural anticoagulants, including PC, are 
consumed; EPCR and thrombomodulin expression is downregu-
lated, decreasing the anticoagulant and antiinflammatory effects 
of the PC pathway. Damaged ECs undergo apoptosis, which fur-
ther amplifies the coagulation cascade (85), leading to enhanced 
microvascular coagulation and EC dysfunction. Ultimately, 
microvascular function is compromised, and local tissue perfusion 
is decreased. Pretreatment or postinjury treatment with soluble 
thrombomodulin attenuates ischemic AKI by reducing vascular 
permeability defects, minimizing wbc-endothelial interactions, 
thus improving microvascular perfusion (77).
Dynamic interactions between ECs and leukocytes play a crit-
ical role in AKI-related inflammation. Rolling leukocytes are 
activated by the chemoattractants complement C3a, C5a, and 
platelet activating factor and interact with endothelial adhesion 
molecules, which are upregulated during ischemic conditions, 
especially in the cortical medullary region where S3 segments 
are located (86). Both C3a and C5a also promote ischemic injury 
via epithelial cells and circulating leukocytes (87). The level of 
ischemic injury–mediated by neutrophils is primarily determined 
by expression of platelet P-selectin (86). Blockade of the shared 
ligand to all three selectins (E-, P-, and L-selectin), which appears 
to be dependent on the presence of a key fucosyl sugar on the 
selectin ligand, led to reduced injury and mortality. Further, 
mice genetically deficient for E-selectin or P-selectin or both were 
completely protected in the cecal ligation and puncture model 
(CLP), a preclinical model for sepsis (88, 89).
The endothelial permeability barrier is defined by a combination 
of transcellular and paracellular pathways, the latter being a major 
contributor to the inflammation-induced barrier dysfunction 
with an important role in the extension phase of ischemic AKI (90, 
91). Increased microvascular permeability results from loss of the 
endothelial monolayer, alterations in the actin cytoskeleton and 
EC contacts, breakdown of the perivascular matrix, upregulation 
of leukocyte-endothelial interactions, and a severe loss of integ-
rity of the adherens junctions of the renal microvasculature (75). 
Sutton and colleagues studied the role of ECs in AKI in a series of 
experiments using fluorescent dextrans and two-photon intravital 
imaging. They observed a loss of capillary barrier function begin-
ning within 4 hours of reperfusion with maximal effects seen at 
24 hours after injury. Breakdown of barrier function was due in part 
to MMP-2 or -9 activation, which was temporally correlated with 
an increase in microvascular permeability (78, 90). Minocycline, a 
broad-based MMP inhibitor, and the gelatinase-specific inhibitor, 
ABT-518, both ameliorated this increased microvascular permea-
bility. Additionally, in experiments described above, Melican and 
colleagues showed that crosstalk between injured PTCs and ECs led 
to increased microvascular permeability and coagulation abnormal-
ities (65, 66). These data indicate direct PTC to EC communication 
and subsequent permeability and coagulation abnormalities.
Ischemic AKI also results in vasoconstriction characterized by an 
imbalance in eNOS and iNOS activity. Loss of normal eNOS func-
tion has been attributed to a loss of vasodilator responses to acet-
ylcholine and bradykinin (92, 93). Selective inhibition, depletion, 
or deletion of iNOS has clearly shown renoprotective effects dur-
ing ischemia (92, 93). It was proposed that with a relative decrease 
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in eNOS, secondary to endothelial dysfunction and damage, there 
is a loss of antithrombogenic properties of the endothelium lead-
ing to increased susceptibility to microvascular thrombosis (94). 
Administration of the L-arginine NO donor molsidomine or 
the eNOS cofactor tetrahydrobiopterin can preserve medullary 
perfusion and attenuate IRI-induced AKI; conversely, the admin-
istration of N-nitro-L-arginine methyl ester, an NO blocker, has 
been reported to aggravate the course of AKI following IRI (95, 96).
Activation of ECs, likely by substances released during AKI tis-
sue injury such as ROS, heat shock proteins, high-mobility group 
protein B1, and ECM fragments, leads to increased outer medul-
lary TLR2 and TLR4 expression, which likely leads to enhanced 
expression of cell adhesion molecules CD54 and CD62E. TLR 
expression was highest in outer medullary cells, the area with the 
greatest amount of inflammation after ischemic AKI (97). The time 
course of TLR4 expression following injury was highest at 4 hours, 
the same point at which the microvasculature begins to show dys-
function (75). In a series of studies using both rats and mice, LPS 
and CLP resulted in rapid loss of cortical peritubular microvascular 
flow, enhanced Icam1 mRNA expression, increased capillary per-
meability, and oxidant production. Moreover, tubular cell ischemic 
stress was highly correlated with the percentage of dysfunctional 
capillaries (98–100). These data imply a direct link between PTC 
epithelial injury and endothelial activation leading to enhanced 
inflammation, coagulation, reduced microvascular flow, and exten-
sion of injury, especially in the outer medullary region.
AKI-induced EC injury has long-term chronic disease implica-
tions. Basile and colleagues documented significant reductions in 
blood-vessel density following acute ischemic injury, leading to the 
phenomenon of vascular dropout (101). This result was verified by 
Sutton and colleagues, who found a nearly 45% drop in vascular 
density 4 weeks after an ischemic insult (102). These data suggest 
that, unlike the renal epithelial tubular cells, the renal vascular 
system lacks comparable regenerative potential. It is not clear yet 
whether apoptosis and necrosis play a major role in EC dropout. 
Ischemia has been shown to inhibit the angiogenic protein VEGF, 
while inducing the putative VEGF inhibitor ADAMTS-1 (103). It 
was then postulated that the lack of vascular repair could be due to 
VEGF deficiency, as shown by experiments where administration 
of VEGF-121 preserved microvascular density (104). This reduc-
tion in microvasculature density is thought to mediate increases in 
hypoxia-mediated HIF production and fibrosis and alters proper 
hemodynamics, leading to hypertension, which may accelerate 
CKD progression following initial recovery from IRI-induced AKI 
(101, 105). Vascular dropout may also predispose patients to recur-
rent ischemic events and AKI (106). Impaired endothelial prolif-
eration and endothelial-to-mesenchymal transition have been 
shown to occur following IRI and are proposed to play a role in 
microvascular rarefaction (107).
Dendritic cells
Dendritic cells are a resident population of bone marrow-derived 
cells and, along with macrophages, form a network between the 
basement membranes of tubular epithelia and peritubular ECs 
(108, 109). While often considered as distinct cell types with 
characteristic functions, recent data have shown considerable 
overlap in cell surface markers and function between DCs and 
macrophages (110). Located in the interstitial space, they have 
access to endogenous and exogenous DAMPS and PAMPS released 
by epithelial cells, invading organisms, and infiltrating cells and 
thus, are key initiators, potentiators, and effectors of the innate 
immune system. DCs have enormous plasticity and can either be 
antiinflammatory or proinflammatory (111, 112). In ischemic AKI 
they recruit inflammatory cells and are the earliest producers of 
IL-6, TNF-α, MCP-1, and RANTES (113), but also participate in 
recovery via IL-10 production (114).They can also be involved in 
producing tolerance by inducing T cell anergy or depletion or by 
inducing Tregs (115). Deletion of DCs reduced IRI, and deletion 
of S1pr3 or inhibition of S1PR2 resulted in protection from IRI 
(116–118). Finally, DCs migrate away from the kidney via the 
lymphatic system to present antigen and regulate lymphocytic 
responses. Thus DCs mediate and amplify communication 
between the epithelium and endothelium, regulating both innate 
and adaptive immunity, self-tolerance, tissue injury, and repair. 
This signal amplification and subsequent targeting serves to 
enhance and spread signaling cascades.
Pericytes
Inflammation and fibrosis have taken center stage since the asso-
ciation and likely synergistic effects of AKI and CKD were recog-
nized and confirmed. Microvascular rarefaction and fibrosis are 
common threads in loss of kidney function following both acute 
and chronic injury (101, 104, 107). While the myofibroblast is the 
cell type responsible for depositing collagen, the source of myo-
fibroblast precursors has not been resolved. In addition to inter-
stitial fibroblasts, which are known to transition, pericytes as well 
as DCs, ECs, and epithelial cells have been identified as poten-
tial contributors to the myofibroblast population (107). Several 
studies now place the pericyte at the crossroads of microvascular 
dropout and therefore, chronic hypoxia and CKD progression 
after AKI (119, 120), although differences in opinions exist (121). 
Using an unbiased approach to identify pericyte genetic altera-
tions in injury, Schrimpf and colleagues found increased activa-
tion and expression of ADAMTS1 and downregulation of tissue 
inhibitor metalloproteinase 3 (TIMP3) (122). TIMP3 stabilized 
pericytes and maintained collagen capillary tube networks, while 
ADAMTS1-treated pericytes enhanced destabilization. Further-
more, TGF-β1 has recently been shown to activate the pericyte/
myofibroblast transition, lending further support for pericyte 
involvement in fibrosis (123). Injured epithelial cells reduce VEGF 
production and increase TGF-β and PDGR, which enhance peri-
cyte dedifferentiation into myofibroblasts. Finally, PDGFR block-
ade on pericytes or VEGFR-2 on ECs led to a reduction in fibrosis 
and stabilization of the microvasculature in the unilateral ure-
thral obstruction (UUO) model (124). Thus, numerous factors 
favor microvascular maladaptation after injury with signals from 
epithelial and/or ECs mediating pericyte activation and transfor-
mation into fibrosis-producing myofibroblasts. These events also 
suggest several epithelial- and endothelial-specific therapeutic 
targets that could limit microvascular dropout and loss of kidney 
function secondary to the fibrotic process. On a cautionary note, 
much of the data generated with regard to pericytes comes from 
the UUO model, which is highly fibrogenic, and not typical of AKI 
models; data from this model should be interpreted with caution 
in relation to AKI.
Summary
Under physiologic conditions the epithelial/endothelial axis, 
which includes DCs and pericytes as amplifiers and mediators, is 
maintained by cell-cell interactions and soluble mediators, about 
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which little is known. With injury, bacterial invasion, systemic sep-
sis, or nephrotoxic drug exposure these interactions are replaced 
by injurious substances including endogenous and exogenous 
DAMPS, which set off signaling cascades of local inflammatory 
mediators that induce local injury and recruitment of profes-
sional inflammatory cells including PMNs, macrophages, NK, 
NKT, and B cells. This recruitment results in adaptive or maladap-
tive responses leading to tissue repair or terminal fibrosis and 
microvascular rarefaction, respectively.
To generate therapeutic advances, several new approaches must 
be adopted. Preclinical studies must be carried out or confirmed 
in CKD and/or aging models either in multiple strains or out-
bred lines. Cell-specific changes must be understood to allow for 
accurate therapeutic targeting, including the glomerulus. Finally, 
translation requires marked improvement in diagnostic studies 
to allow for individualization of care for this heterogenous syn-
drome. These additional approaches are required to understand, 
minimize, and regulate local cell-cell interactions and their 
responses to injury in an attempt to avoid the terminal cascades. 
It may be difficult to inhibit the later inflammatory-mediated pro-
cesses without nonselective systemic immune suppression. There-
fore, it is reasonable to consider selective therapies that minimize 
PTC and/or EC injury or responses to injury/DAMPS to limit 
downstream activation and amplification. An example of the need 
for selective inhibition comes from targeted p53 inhibition. Selec-
tive inhibition of p53 in PTCs by siRNA (52) or via PTC-specific 
p53 knock out in mice (60) prevented p53 upregulation and pro-
vided protection from ischemic AKI; however, the nonselective p53 
inhibitor pifithrin-α increased fibrosis and microvascular rarefac-
tion in rats following IRI (125). In p53 knockout mice, IRI resulted 
in worse acute injury and increased fibrosis (10, 113). The authors 
concluded that inhibition of leukocyte p53 increased the extent 
and duration of inflammation, thus increasing the inflammatory 
and fibrotic response. These studies highlight the importance of 
understanding cell-specific responses and being able to target 
them in a selective fashion in individual patients.
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